{"nctId":"NCT01867164","briefTitle":"A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis","startDateStruct":{"date":"2007-12"},"conditions":["Vaginitis","Infectious Vaginosis"],"count":160,"armGroups":[{"label":"Gynoclin V","type":"EXPERIMENTAL","interventionNames":["Drug: Gynoclin V"]},{"label":"Vagitrol V","type":"EXPERIMENTAL","interventionNames":["Drug: Vagitrol V"]}],"interventions":[{"name":"Gynoclin V","otherNames":[]},{"name":"Vagitrol V","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants presenting clinical symptoms compatible with vaginitis/bacterial vaginosis, with any of the following symptoms being the reason for the consultation: pruritus (itchiness), vulvar burning, as well as presenting leukorrhea (a clear or white discharge from the vagina, consisting mainly of mucus) as an accompanying symptom\n* Participant who agrees to return at the 7th and 13th day after starting the treatment\n* Participant who agrees to abstain from sexual relations for the 13 days of the study\n* Participant who have signed informed consent to participate in the study\n\nExclusion Criteria:\n\n* Participant with a known allergy to vaginal treatments\n* Participants who have received treatment for the current condition in the 10 days before the date of inclusion, or is currently receiving antibiotics (drug used to stop or slow down the growth of germs), antifungals, anti-parasitics or systemic steroids\n* Participant with suspected pregnancy or currently breastfeeding\n* Participant who has received unknown drugs or experimental drugs within the 3 months before inclusion\n* Participant known to be a carrier of a severe (very serious, life threatening) disease that alters the metabolism or excretion of the drugs used (liver or kidney disease)","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Presence or Absence of Symptoms 3 Days After Treatment","description":"Participants were evaluated for presence or absence of symptoms (itching, burning and sudden vulvar pain) in response to treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.1","spread":null},{"groupId":"OG001","value":"79.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.9","spread":null},{"groupId":"OG001","value":"20.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.5","spread":null},{"groupId":"OG001","value":"88.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.5","spread":null},{"groupId":"OG001","value":"11.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.0","spread":null},{"groupId":"OG001","value":"90.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"9.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Presence or Absence of Symptoms 8 Days After Treatment","description":"Participants were evaluated for presence or absence of symptoms (itching, burning and sudden vulvar pain) in response to treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.3","spread":null},{"groupId":"OG001","value":"85.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":null},{"groupId":"OG001","value":"14.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.5","spread":null},{"groupId":"OG001","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.4","spread":null},{"groupId":"OG001","value":"89.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":null},{"groupId":"OG001","value":"10.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With the Presence of Microorganisms (Single-celled, Tiny Organisms That Include Fungi, Bacteria, Viruses) 3 Days After Treatment","description":"Percentage of participants with the presence of microorganisms (Candida albicans, Candida species, Gardnerella vaginalis, Vaginal flora, Lactobacillus species) in the wet mount, KOH, gram stain and vaginal discharge culture (candida and symptomatology) 3 days after treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":null},{"groupId":"OG001","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.6","spread":null},{"groupId":"OG001","value":"58.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.4","spread":null},{"groupId":"OG001","value":"36.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"3.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Response to Treatment Assessed by Participant","description":"Response to treatment was evaluated by participant using a 5-point numerical scale: 1=No response (no improvement or condition even worsened); 2=Poor (No symptoms disappeared and symptoms are moderate to severe) 3=Moderate (improvement and symptoms are of moderate intensity); 4=Good (much improvement, but there are still some occasional mild symptoms); 5=Excellent (all symptoms disappeared).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.30","spread":null},{"groupId":"OG001","value":"1.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.40","spread":null},{"groupId":"OG001","value":"29.40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.30","spread":null},{"groupId":"OG001","value":"65.30","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Response to Treatment Assessed by Physician","description":"Response to treatment was evaluated by Physician using a 5-point numerical scale: 1=No response (no improvement or condition even worsened); 2=Poor (No symptoms disappeared and symptoms are moderate to severe) 3=Moderate (improvement and symptoms are of moderate intensity); 4=Good (much improvement, but there are still some occasional mild symptoms); 5=Excellent (all symptoms disappeared).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.30","spread":null},{"groupId":"OG001","value":"1.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"5.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.60","spread":null},{"groupId":"OG001","value":"26.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.10","spread":null},{"groupId":"OG001","value":"66.70","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":81},"commonTop":["Fungal Infections","Headache"]}}}